S100A9 and cancer: In general, MDSC-induced immunosuppression is mediated through the orchestration of multiple pathways, including direct cell-to-cell interactions and the production of immunosuppressive factors such as ARG1, NOS, S100A8, and S100A9, leading to cancer progression and interference with the efficacy of therapeutic agents such as immune checkpoint inhibitors [30–34].